中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
9期
75-76
,共2页
常淑平%王韫芳%杨冉%付秀云
常淑平%王韞芳%楊冉%付秀雲
상숙평%왕운방%양염%부수운
左卡尼汀%老年%血液透析%低血压
左卡尼汀%老年%血液透析%低血壓
좌잡니정%노년%혈액투석%저혈압
levocarnitine%elderly%hemodialysis%hypotension
目的：观察左卡尼汀对老年维持性血液透析低血压的改善效果并分析其安全性。方法选择2009年1月至2013年1月收治的老年血液透析患者120例为观察组，在常规透析基础上加用左卡尼汀治疗，选取同时期老年患者48例为对照组进行常规透析治疗。主要观察两组患者透析前和透析过程中收缩压、舒张压的最低血压值，检测尿素氮(BUN)、血肌酐(SCr)、24 h蛋白尿(g)的含量，记录透析过程中及透析后患者不良反应及低血压发生率。结果观察组透析过程中，最低收缩压和舒张压分别为（81.57±4.97）mmHg 和（60.44±3.95）mmHg，均明显低于透析前，且观察组高于对照组（ P＜0.05）。观察组透析后 BUN、SCr 和24 h 蛋白尿含量分别为（17.24±1.93）mmol/L，（251.47±14.82）μmol/L和（2.06±0.17）g，均低于对照组透析后( P＜0.05)。观察组透析过程中及透析后不良反应发生率为9.17%(11/120)，对照组为18.75%(9/48)，差异无统计学意义( P＞0.05)。观察组低血压发生率为15.83%（19/120），低于对照组的35.42%（17/48），差异具有统计学意义( P＜0.05)。结论左卡尼汀能明显改善老年维持性血液透析低血压，提高透析过程的安全性。
目的：觀察左卡尼汀對老年維持性血液透析低血壓的改善效果併分析其安全性。方法選擇2009年1月至2013年1月收治的老年血液透析患者120例為觀察組，在常規透析基礎上加用左卡尼汀治療，選取同時期老年患者48例為對照組進行常規透析治療。主要觀察兩組患者透析前和透析過程中收縮壓、舒張壓的最低血壓值，檢測尿素氮(BUN)、血肌酐(SCr)、24 h蛋白尿(g)的含量，記錄透析過程中及透析後患者不良反應及低血壓髮生率。結果觀察組透析過程中，最低收縮壓和舒張壓分彆為（81.57±4.97）mmHg 和（60.44±3.95）mmHg，均明顯低于透析前，且觀察組高于對照組（ P＜0.05）。觀察組透析後 BUN、SCr 和24 h 蛋白尿含量分彆為（17.24±1.93）mmol/L，（251.47±14.82）μmol/L和（2.06±0.17）g，均低于對照組透析後( P＜0.05)。觀察組透析過程中及透析後不良反應髮生率為9.17%(11/120)，對照組為18.75%(9/48)，差異無統計學意義( P＞0.05)。觀察組低血壓髮生率為15.83%（19/120），低于對照組的35.42%（17/48），差異具有統計學意義( P＜0.05)。結論左卡尼汀能明顯改善老年維持性血液透析低血壓，提高透析過程的安全性。
목적：관찰좌잡니정대노년유지성혈액투석저혈압적개선효과병분석기안전성。방법선택2009년1월지2013년1월수치적노년혈액투석환자120례위관찰조，재상규투석기출상가용좌잡니정치료，선취동시기노년환자48례위대조조진행상규투석치료。주요관찰량조환자투석전화투석과정중수축압、서장압적최저혈압치，검측뇨소담(BUN)、혈기항(SCr)、24 h단백뇨(g)적함량，기록투석과정중급투석후환자불량반응급저혈압발생솔。결과관찰조투석과정중，최저수축압화서장압분별위（81.57±4.97）mmHg 화（60.44±3.95）mmHg，균명현저우투석전，차관찰조고우대조조（ P＜0.05）。관찰조투석후 BUN、SCr 화24 h 단백뇨함량분별위（17.24±1.93）mmol/L，（251.47±14.82）μmol/L화（2.06±0.17）g，균저우대조조투석후( P＜0.05)。관찰조투석과정중급투석후불량반응발생솔위9.17%(11/120)，대조조위18.75%(9/48)，차이무통계학의의( P＞0.05)。관찰조저혈압발생솔위15.83%（19/120），저우대조조적35.42%（17/48），차이구유통계학의의( P＜0.05)。결론좌잡니정능명현개선노년유지성혈액투석저혈압，제고투석과정적안전성。
Objective To investigate the clinical improvement effect of levocarnitine on elderly maintenance hemodialysis hypotension and to analyze its security in order to provide the basis for clinical rational treatment. Methods 120 hemodialysis elderly patients in our hospital from January 2009 to January 2013 were selected as the observation group and used the levocarnitine therapy on the basis of conventional dialysis. Contemporaneous 48 elderly patients were selected as the control group and performed the routine dialysis treat-ment. The lowest blood pressure values of systolic and diastolic blood pressure before and during dialysis were observed. The renal in-dexes of blood urea nitrogen ( BUN ) and serum creatinine ( SCr ) , and 24 h urine protein ( g ) were detected. The occurrence rates of adverse reactions and hypotension during and after dialysis were also recorded. Results The lowest systolic and diastolic blood pressure during the dialysis process in the observation group were ( 81. 57 ± 4. 97 ) mmHg and ( 60. 44 ± 3. 95 ) mmHg respectively, which were significantly lower than those before dialysis, moreover the observation group was higher than the control group, the differences were sta-tistically significant ( P < 0. 05 ) . BUN, beta 2-MG and 24 h urine protein of the observation group after dialysis were ( 17. 24 ± 1. 93 ) mmol/L, ( 251. 47 ± 14. 82 ) mg/L and ( 2. 06 ± 0. 17 ) g, which were lower than those after dialysis in the control group, the differences were statistically significant ( P < 0. 05 ) . The adverse reactions during dialysis process and after dialysis was 9. 17% ( 11/120 ) in the observation group and 18. 75% ( 9/48 ) in the control group, the difference had no statistically significant ( P > 0. 05 ) . The incidence rate of hypotension in the observation group was 15. 83% ( 19/120 ) , which was lower than 35. 42% ( 17/48 ) in the control group, the difference was statistically significant ( P < 0. 05 ) . Conclusion Levocarnitine could significantly improve the elderly maintenance hemodialysis hypotension and increases the safety of dialysis process.
